Bachem stock slips as investors weigh 76.22 CHF trading and 5.77 billion CHF value
Published on 08/31/2026 at 15:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bachem stock (CH0012530207) fell 1.8 percent to 75.60 CHF on August 31, 2026, after trading showed an intraday low of 75.05 CHF and a session start at 76.15 CHF.
Trading tone
The latest quote snapshot also placed the share at 76.22 CHF with a daily change of -0.38 percent, and turnover reached 11,664 shares by 12:28 p.m. on August 31, 2026. The market value stood at 5.77 billion CHF, which gives the move a clear size context.
Latest reported picture
The most recent report-linked figures visible in the available market coverage point to a revenue base of 495.4 million CHF in the first half of 2025 and an EBITDA margin of 22.1 percent for that period. Historical context from the same coverage also shows that net income was 49.4 million CHF in the first half of 2025, a solid comparison point against current trading sentiment.
Read more
Investor attention is still centered on the company's peptide and oligonucleotide manufacturing platform, where capacity use and order timing tend to matter more than broad market moves.
Product line
The core business remains built around custom synthesis and large-scale manufacturing for active pharmaceutical ingredients, with peptide-based projects the main commercial lever for a group like Bachem.
Price context
Bachem shares traded at 75.60 CHF on August 31, 2026, against a cited quote of 76.22 CHF earlier in the session. The latest trading range in the snapshot stretched from 75.05 CHF to 76.15 CHF.
Company profile
Company: Bachem AG
ISIN: CH0012530207
Ticker: BCHN
Exchange: SIX Swiss Exchange
Price (as of August 31, 2026, 12:28 p.m. ET): CHF 75.60
Market cap: CHF 5.77 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: SPI
